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Abstract
The current paradigm for biomedical research and drug testing postulates that in vitro and in
silico data inform animal studies that will subsequently inform human studies. Recent evi-
dence points out that animal studies have made a poor contribution to current knowledge of
Major Depressive Disorder, whereas the contribution of in vitro and in silico studies to animal
studies- within this research area- is yet to be properly quantified. This quantification is
important since biomedical research and drug discovery and development includes two
steps of knowledge transferability and we need to evaluate the effectiveness of both in order
to properly implement 3R principles (Replacement, Reduction and Refinement). Here, we
used the citation tracking facility within Web of Science to locate citations of original
research papers on in vitro and in silico related to MDD published identified in PubMed by
relevant search terms. 67 publications describing target papers were located. Both in vitro
and in silico papers are more cited by human medical papers than by animal papers. The
results suggest that, at least concerning MDD research, the current two steps of knowledge
transferability are not being followed, indicating a poor compliance with the 3R principles.
1. Introduction
Biomedical research heavily relies on animal studies, despite the ethical and clinical limitations
of these [1].
The standard contemporary paradigm for biomedical research, and drug discovery and
development, requires scientists to test putative new clinical interventions, by progressing
from simple to increasingly complex models, prior to conducting human studies and trials, as
shown in Fig 1.
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Even though this paradigm is more focused toward drug discovery, it is also encouraged for
broader research, by legislation and guidelines pertaining to animal research, in various coun-
tries and regions (e.g.[3]).
Supporters of animal studies within biomedical research claim that 1) it is not possible to
discontinue their use, as that would jeopardize human health, and that 2) human-based meth-
ods (in silico and in vitro) are used in early steps of biomedical research to inform the animal
research community, hence avoiding unnecessary or excessive use of animals. For example,
purportedly, if a substance shows high levels of toxicity in vitro it will not progress into animal
testing [4]. In the same way, a drug that shows high toxicity in animal testing should not pro-
ceed to human trials. However, it has been demonstrated that human trials may sometimes
occur simultaneously with animal trials, rather than sequentially, as one would expect if animal
trials were an essential step prior to human trials [5].
In our previous study we compared the number of citations in vitro, in silico and non-
human primate-based (NHP) original studies focused on Major Depressive Disorder (MDD),
that were received (i) in total, (ii) by unspecified human medical papers, and (iii) by human
medical papers focused on MDD. We verified that both in vitro and in silico research papers
received more citations by human medical papers, than NHP papers. This was unexpected,
considering that most countries restrict the use of NHPs, making it reasonable to presume that
when they were used, they should provide a significant contribution to human health. How-
ever, this was not the case. Data obtained via simpler models (in vitro and in silico) seemed to
be more visible or considered more important by the human medical research community.
This called into question the contemporary paradigm of biomedical research and drug discov-
ery, in which knowledge is presumed to transfer between animal and human models [6].
Considering that this paradigm presumes two steps of knowledge transferability: i) between
simpler and complex models, and ii) between animals models and humans, we wondered if
there could be knowledge transferability problems in step (i), similar to those we demonstrated
at step (ii).
Hence, the aim of the current study is to assess whether in vitro and in silico papers describ-
ing original data on a human disorder (MDD) are being appropriately cited by subsequent ani-
mal-based papers. It is important to mention that animal models are extensively used in MDD
research. In fact, by the time our study was conducted there were about twice as many original
papers using animal models in MDD research than papers using in vitro and in silico
approaches.
During studies focused on MDD, animals frequently undergo severe procedures such as
learned helplessness or forced swim test protocols. Most applicable legislations and guidelines
mandate that such procedures should be avoided wherever possible. Hence it is reasonable to
expect that the MDD-focused animal research community should be particularly alert to the
data and insights provided by simpler data.
Even though there is a wide consensus that the use of simpler models such as in vitro and in
silico methods within basic and applied biomedical research helps animal researchers to meet
the principles of Replacement (of animals with alternatives) and Reduction (of animal num-
bers), as described by Russell & Burch [7], to our knowledge, there has never been a systematic
Fig 1. Current paradigm of biomedical research and drug discovery and development. Kindly provided by Taylor [2].
https://doi.org/10.1371/journal.pone.0233954.g001
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study that empirically verifies whether animal researchers are, indeed, applying this principles
to their practice i.e. if they are locating and using applicable data obtained via such simpler
models.
If in vitro and in silico studies are indeed seen as an important step prior to conducting ani-
mal studies in biomedical research, and animal studies are in turn seen as important prior to
conducting human studies, then we would expect that papers describing in vitro or in silico
data on a human disorder should be cited more frequently by animal papers, than by human
medical papers. If, on the contrary, this is not the case, then further studies on other human
disorders and drug development should be conducted to confirm the extent to which the con-
temporary theoretical paradigm for biomedical research is actually being followed in practice.
If adherence is not as common as believed, then this paradigm should clearly be revised.
2. Methods
We conducted a citation analysis as defined by Garfield and Merton [8]. Concisely, in a cita-
tion analysis, target papers are located first and then a search for all other papers citing the for-
mer is performed.
The information compiled comprises the total number of citations, and the patterns of cita-
tion. We used a total of 67 target papers of in vitro or in silico studies on MDD- utilising only
human data, selected from the citation analysis database created in our previous study [6]. The
citation analysis was performed between September 2016 and June 2017. We considered all
published papers using in vitro or in silico methods, that aimed to gain knowledge about
MDD, and were published prior to 2011, to enable five-year time for citations–a frequently
used timeline for citation analysis [9]. To locate target papers we searched PubMed–the largest
freely accessible bibliographic database, using the following Medical Subject Heading (MeSH)
search terms: ‘Depressive Disorder, Major’ AND (“in silico” OR ‘computer model’ OR ‘mathe-
matical model’ OR ‘computer simulation’ OR ‘in vitro’ OR ‘cell culture’ OR ‘culture technique’
OR ‘cell line’ OR ‘organ culture’ OR ‘tissue culture’. Our goal was to select original publications
that presented new data, so we used PubMed filters to exclude review articles (“review”, “sys-
tematic review”, “meta-analysis”, “bibliography”) as well as opinion articles (“biography”,
“autobiography”, “comment”, “editorial”, “interview”). We also excluded by hand in vitro
papers that used animal tissue or cells. Using the citation tracking facility within Web of Sci-
ence, we counted the number of times each target paper was cited by subsequent papers in the
following categories: ‘animal research papers‘, ‘human medical papers‘, ‘in vitro papers‘, and
‘in silico papers‘. Citing papers may have been assigned to more than one category if they
described different research approaches (e.g. human-based and in vitro).
3. Results
In total, 464 (18%) of the 2,574 citations received by the 38 in vitro papers were by invasive ani-
mal research papers, and 978 (40%) were by human medical papers. For the 29 in silico papers,
44 (5%) of the 806 citations were by invasive animal research papers, and 317 (39%) by human
medical papers.
As shown in Fig 2, the majority of citations received by both in vitro or in silico target papers
were by papers employing the same research method, and by human medical papers. The pro-
portion of citations by animal papers and the other research method were considerably lower.
More importantly, the proportion of citations by animal papers was lower than by human
medical papers.
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4. Discussion
The results of our citation analysis suggest that the standard approach to testing medical
hypotheses–which postulates that in vitro and in silico research is an important step prior to
conducting animal testing–is not supported by citation data, at least for MDD research.
Clearly, MDD biomedical research utilising in vitro and in silico data does not seem to be con-
sidered important by, or at least more important to, the animal research community, than it is
to the human medical community.
One can argue that if the animal research community is not citing in vitro and in silico
papers on MDD, these might be of limited use. However, that is inconsistent with their sub-
stantial use by the human medical community, which cites more this kind of research than
research based on animal studies [6]. Additionally, this lack of transferability of knowledge
between the animal and the human medical research communities is further evidenced by the
fact that, in general, most citations received by animal research papers are within other ani-
mal-based studies, rather than within human medical papers [10].
MDD is a complex human mental disorder with multifactorial aetiopathogenesis [11], so
one cannot extrapolate that the citation patterns found here will necessarily be replicated in
other disorders that have just one cause (e.g. Down’s syndrome). Furthermore, a single disease
analysis is not enough to generalize the results to the entire field of biomedical research.
Hence, the next step should be the use of a similar approach targeting monofactorial disor-
ders and drug trials. If, as whole, these studies produce similar results, then it would be com-
pelling evidence that the accepted paradigm for biomedical research and drug discovery and
Fig 2. Boxplots of the proportion of citations received by research category for in vitro A) and in silico B) papers on
MDD.
https://doi.org/10.1371/journal.pone.0233954.g002
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development is not being sufficiently followed, which supports the claims made by several
authors [1] that the 3Rs are not being addressed as well as required by applicable legislation
and good research practice. This suggests that animal studies in biomedical research are mostly
defining their research priorities autonomously, rather than being perfectly framed in the bio-
medical research paradigm.
Sixty years ago Russell and Burch [7] established the foundations of much current legisla-
tion regarding animal experimentation, with the formulation of the 3R principles. Even
though the research community unanimously welcomes them, the focus of their application
has predominantly been refinement, and not always in an effective way [1].
Nowadays there is an increasing number of databases on human and animal protein
expression differences (for a review see [12]) which, on the one hand, makes it easier for
researchers to locate and cite existing data; but, on the other hand, might stimulate animal
research to be conducted independently of in vitro and in silico data to populate such
databases.
In theory, the reduction principle depends upon the standard use of in silico and in vitro
techniques prior to animal studies. If original data on human disorders from in vitro and in sil-
ico approaches are not being used by the animal research community, then the reduction prin-
ciple is not being properly fulfilled. The reasons behind this must surely be multiple.
One of the possible reasons is the inadequacy of systematic reviews that animal researchers
sometimes perform on their research topic, prior to conducting animal experiments. These
should prevent unnecessary animal use [13], but by excluding from the search in vitro and in
silico studies, researchers can exclude an important source of knowledge.
Based on our results we recommend that changes are made in current systematic review
protocols in order to include in vitro and in silico data.
Another reason that became salient with our study and deserves attention, is that in vitro
and in silico approaches are, by definition, human-based methods, not animal-based methods.
Conceivably human data is not relevant enough for animal papers, in the same way animal
studies do not seem to be relevant to subsequent human studies [6,10].
This highlights that the current paradigm of biomedical research and drug discovery and
development includes two steps of knowledge transferability between the animal and the
human models, neither of which appear to work well. If similar results are found in other dis-
orders and more importantly, in drug discovery, than the current paradigm must be changed.
Specifically, animal testing must be deprioritized, with greater investment in human-based in
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